Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Lexicon Pharmaceuticals announced that its management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, highlighting its ongoing commitment to investor communication and showcasing its diverse drug pipeline focused on neuropathic pain, hypertrophic cardiomyopathy, obesity, and cardiometabolic disorders.

LXRX

Summarize with

ChatGPT Perplexity Claude Grok Gemini

Key Points

Lexicon will present at a major investor conference held at Nasdaq headquarters, enhancing investor visibility.
The company is advancing multiple drug candidates in various stages targeting neuropathic pain, HCM, obesity, and metabolic disorders.
The event provides an opportunity to engage with investors and emphasize corporate strategy and pipeline progress.

THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C. Wainwright BioConnect Investor Conference, taking place at the Nasdaq World Headquarters in New York City, on May 19, 2026.

The live event and a replay of the presentation can be accessed via the Events page of the Company’s website at https://investors.lexpharma.com/.

About Lexicon Pharmaceuticals
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.

For Media Inquiries:
Dave Belian
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

For Investor Inquiries:
Lisa DeFrancesco
Lexicon Pharmaceuticals, Inc.
lexinvest@lexpharma.com

Risks

Drug development inherently carries clinical trial, regulatory, and commercial risk across its pipeline targets, including neuropathic pain and cardiometabolic diseases.
Potential delays or setbacks in clinical trials may impact timelines and investor sentiment.
Competitive pressures in biopharmaceutical sectors focused on metabolic and cardiometabolic conditions could affect market positioning.

Menu

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Key Points

Risks

More from Press Releases